Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382885 · ClinicalTrials.gov registry record · Phase 1
Cariprazine Pediatric ASD PK Study
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04382885 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 24 participants.
The verdict
NCT04382885, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will be a multi-center, open-label, parallel-group, multiple-dose study in up to 24 male and female participants aged 5 through 17 years, inclusive, with Autism Spectrum Disorder (ASD). The 24 participants will be enrolled into 1 of 4 cohorts (6 participants per cohort).
Interventions
- DRUG Cariprazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-06-26 |
| Est. Completion | 2021-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04382885
The ClinicalTrials.gov registry entry for NCT04382885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cariprazine is the first listed.
NCT04382885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04382885 about?
NCT04382885 is a clinical study titled "Cariprazine Pediatric ASD PK Study". This study will be a multi-center, open-label, parallel-group, multiple-dose study in up to 24 male and female participants aged 5 through 17 years, inclusive, with Autism Spectrum Disorder (ASD). The 24 participants will be enrolled into 1 of 4 cohorts (6 participants per cohort).
What is the current status of trial NCT04382885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-06-26. Estimated completion is 2021-12-10.
What interventions are being tested in trial NCT04382885?
The interventions under investigation include: Cariprazine (DRUG).
Who is sponsoring clinical trial NCT04382885?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.